Investment Thesis
ImageneBio is a pre-commercial biotech firm with an unsustainable cash burn model: $15.2M annual negative free cash flow against only $800K revenue. While the strong balance sheet ($76M cash, zero debt) provides runway and loss trends are improving, the company remains fundamentally unprofitable with zero revenue growth and no evidence of near-term commercialization. Current burn rate exhausts cash within ~5 years without meaningful revenue inflection.
Strengths
- Excellent financial health with $76M cash and zero long-term debt
- Strong liquidity position (18.39x current ratio) provides operational flexibility
- Improving profitability trend with net losses declining 13.4% YoY and EPS improving 56.4% YoY
Risks
- Severe cash burn of $14.8M operating outflow against negligible $800K revenue is unsustainable
- Zero revenue growth YoY with minimal absolute revenue indicates pre-commercial stage with no near-term monetization
- Biological products sector carries high regulatory, clinical development, and execution risk with uncertain path to profitability
- Burn rate trajectory at current stage exhausts available cash within ~5 years without significant revenue generation
Key Metrics to Watch
- Operating cash flow trend and absolute burn rate per quarter
- Revenue growth trajectory and evidence of clinical/commercial progress
- Cash balance runway relative to operating burn rate
- Insider buying/selling activity and capital raise activity
Financial Metrics
Revenue
800.0K
Net Income
-10.6M
EPS (Diluted)
$-0.95
Free Cash Flow
-15.2M
Total Assets
136.7M
Cash
76.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,509.9%
Net Margin
-1,327.4%
ROE
-8.6%
ROA
-7.8%
FCF Margin
-1,901.8%
Balance Sheet & Liquidity
Current Ratio
18.39x
Quick Ratio
18.39x
Debt/Equity
0.00x
Debt/Assets
9.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:21:40.953457 |
Data as of: 2026-03-31 |
Powered by Claude AI